I think perhaps I sit somewhere in the middle on the issue of RVX and conference attendance/roadshows. I think it is very important that members of the science team continue to attend the scientific conferences as I think that this is an important part of gaining acceptance in the scientific community at large. We need more acceptance and coverage from analysts like David Kideckel and any reputable scientific publication will always further the cause. 

Where I believe RVX falls way short is credibility on the business side. There is no one in the business executive who has any biotech track record in terms start up/development through successful disposition of a biotech company/compound.  The only people with this type of experience at RVX are on the science side and they seem to have a very limited role in terms of giving a professional face to the company. The CEO/Chairman has zero identified business or scientific experience in biotech/pharma and to me someone with no track record should not be the one trying to win over investors. I think this gives investors way to little credit and, so far at least, their approach to investors at large has been far less than successful. Unless the company is willing to put the experienced and successful people such as Dr’s Wong, Sweeney and Johannson directly in front of investors I would agree they should stop wasting money on investor conferences. I would also like to see them cease spending money on paid for “coverage” and to focus investor efforts more in Canada until such time they have a first tier US listing. 

All JMO